MINA ALPHA LIMITED

ACTIVE

Translation & Innovation Hub, London, United KingdomPrivate

Clinical Trials

3 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

80.0%

Phase 2

20.0%

Trial Status Distribution

Active, not recruiting

60.0%

Completed

40.0%

Clinical Trials

Trials sponsored by this organization (5)

Safety, tolerability, and efficacy of a combination of MTL-CEBPA and sorafenib in patients with advanced liver cancer with a viral background.

Phase 1

Active, not recruiting

Mar 2022150 participants

Safety, tolerability, and efficacy of a combination of MTL-CEBPA and sorafenib in patients with advanced liver cancer with a viral background.

Phase 1

Active, not recruiting

Jan 2022150 participants

Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone

Phase 2

Completed

interventional

Jan 20228 participants

A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)

Phase 1

Completed

interventional

Nov 201950 participants

First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer

Phase 1

Active, not recruiting

interventional

Mar 201675 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations